Thursday, January 21, 2021

QualityStocksNewsBreaks – HempFusion Wellness Inc. (TSX: CBD.U) Enters Doctor Practitioner Space with Large-Scale Distribution Agreement

 HempFusion Wellness Inc. (TSX: CBD.U), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, has entered into a large-scale distribution agreement with Fullscript.com to launch a doctor practitioner sales channel. Fullscript is a leading eCommerce platform designed to allow health professionals to dispense professional-grade natural health products. Based on the agreement, HempFusion’s seven Biome Research SKUs will be available from Fullscript distribution centers, effective Feb. 2, 2021. The agreement is a significant step in HempFusion’s strategy to enter into the doctor practitioner sales space. Fullscript has become one of the largest distributors in the doctor practitioner sector; the platform offers nutritional supplements to more than 80,000 practitioners and more than 600,000 patients in both the United States and Canada. “We are incredibly excited to launch doctor practitioner sales starting with Biome Research, a specialized wholly owned HempFusion brand designed specifically for doctors, practitioners and their patients,” said HempFusion director of doctor/practitioner Nancy Angelini in the press release. “An industry-leading eCommerce platform like Fullscript, with a deep and established distribution network, is a tremendous advantage to HempFusion. We expect this channel to drive significant revenue growth for the company.”

To view the full press release, visit https://ibn.fm/fBojl

About HempFusion Wellness Inc.

HempFusion is a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition. HempFusion distributes its family of brands, including HempFusion, Probulin Probiotics, Biome Research and HF Labs, to approximately 4,000 retailers across all 50 states of the United States and select international locations. Built on a foundation of regulatory compliance and human safety, HempFusion’s diverse product portfolio comprises 46 SKUs (“SKUs”) including tinctures, proprietary FDA Drug Listed over-the-counter (“OTC”) topicals, doctor/practitioner lines and more. With a strong focus on research and development, HempFusion has an additional 30 products under development. HempFusion is a board member of the US Hemp Roundtable, and HempFusion’s wholly owned subsidiary, Probulin Probiotics, is one of the fastest-growing probiotics companies in the United States, according to SPINs reported data. HempFusion’s CBD products are based on a proprietary Whole Food Hemp Complex(TM) and are available in store or online. For more information about the company, visit www.HempFusion.com.

NOTE TO INVESTORS: The latest news and updates relating to HempFusion are available in the company’s newsroom at https://ibn.fm/HempFusion

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

No comments: